Cosmetic cross-reference Noindex: medium evidence

136-23-2

CAS 136-23-2

136-23-2 (CAS 136-23-2) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
136-23-2
CAS Number
136-23-2
UNII
HNM5J934VP
InChIKey
BOXSVZNGTQTENJ-UHFFFAOYSA-L
ChEMBL ID
CHEMBL2373108
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 7984.633333333334 nM 3 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 136-23-2 used for in pharmaceutical contexts?

136-23-2 (CAS 136-23-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 136-23-2?

No adverse-event association or SIDER side-effect rows are rendered for 136-23-2 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 136-23-2 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for ZINC DIBUTYLDITHIOCARBAMATE with EU status "restricted".

What clinical phase is 136-23-2 in?

No phase 1-4 clinical development badge is rendered for 136-23-2 because the matched compound identifier rows do not contain a max-phase value.